Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ)
Your view on BIOVF
Overview
What the company does, where it operates, and who runs it.
About Swedish Orphan Biovitrum AB (publ)
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Guido Oelkers
- Headquarters
- Tomtebodavägen 23A, Solna, SE
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Guido Oelkers
- Headquarters
- Tomtebodavägen 23A, Solna, SE
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally.
It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.
The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus.
The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Swedish Orphan Biovitrum AB (publ), and the rating behind it. BIOVF last traded at $37.00, 110.4× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Swedish Orphan Biovitrum AB (publ). Starting points for Swedish Orphan Biovitrum AB (publ): P/E 110.4, EPS $3.99, beta 0.18 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Swedish Orphan Biovitrum AB (publ). Swedish Orphan Biovitrum AB (publ) does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Swedish Orphan Biovitrum AB (publ). Trailing twelve-month EPS for Swedish Orphan Biovitrum AB (publ) stands at $3.99. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Swedish Orphan Biovitrum AB (publ). Swedish Orphan Biovitrum AB (publ) has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Swedish Orphan Biovitrum AB (publ) valued side by side against its closest peers. Swedish Orphan Biovitrum AB (publ) is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Swedish Orphan Biovitrum AB (publ), and how their positions are changing. At a $12.79B market value, institutional positions materially move Swedish Orphan Biovitrum AB (publ)'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Swedish Orphan Biovitrum AB (publ) executives and directors. Shares of Swedish Orphan Biovitrum AB (publ) have traded between $25.80 and $41.55 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Swedish Orphan Biovitrum AB (publ). Swedish Orphan Biovitrum AB (publ) is a $12.79B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Swedish Orphan Biovitrum AB (publ). Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Swedish Orphan Biovitrum AB (publ). Coverage tracks Swedish Orphan Biovitrum AB (publ) within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.